ReviewMolecular neurobiology2026
Bisphenol S and Neurological Health: An Integrated Overview of Neurotoxicity and Underlying Mechanisms.
Review in Molecular neurobiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Bisphenol S (BPS), a pervasive contaminant used in consumer and industrial products, has been widely detected in human serum, urine, hair, placenta, and breast milk. Although initially studied mainly as an endocrine disruptor, accumulating evidence indicates that BPS also exerts neurotoxicity by perturbing neuroinflammatory responses, neuroendocrine regulation, and neuronal development. However, its neurotoxic profile and mechanistic basis remain incompletely defined. This review systematically retrieved and synthesized epidemiological, animal, and cellular studies published between 2000 and February 2026 across multiple databases to delineate the neurotoxic features and mechanisms of BPS. Evidence from 14 epidemiological and 76 experimental studies consistently indicates neurotoxic risk. Epidemiological data associate BPS exposure with increased risks of neuropsychiatric outcomes, including attention-deficit/hyperactivity disorder (ADHD), Alzheimer's disease (AD), and depression, often with sex-specific patterns. Animal studies show that exposure across life stages induces behavioral impairments, encompassing social deficits, cognitive and emotional disturbances, motor dysfunction, and memory decline. In vitro studies further elucidate molecular underpinnings. Mechanistically, BPS neurotoxicity involves endocrine-axis disruption, neurotransmitter imbalance, oxidative stress, and transcriptional dysregulation and extends to gut-brain axis perturbation, brain region-specific vulnerability, and neural circuit dysfunction. These pathways interact and are modified by toxicokinetics, exposure dose and timing, sex, and species. Future work should integrate longitudinal human cohorts with mechanistic studies to clarify BPS's contribution to neurological disease development and inform regulation. We propose an integrative framework summarizing BPS neurotoxicity and its key modifying factors.
Indexed as
Identifiers
41790409What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.